What Is CagriSema?
CagriSema is Novo Nordisk's next-generation weight-management drug combining two active ingredients in a single weekly injection: semaglutide (the GLP-1 receptor agonist in Wegovy and Ozempic) and cagrilintide (a long-acting amylin analog). By targeting both the GLP-1 and amylin pathways simultaneously, CagriSema aims to produce greater weight loss than semaglutide alone.
Phase 3 clinical trial data (REDEFINE program) has shown average weight loss of approximately 22–25% of body weight — exceeding Wegovy's ~17% and approaching tirzepatide's ~22% at the highest doses. If approved, CagriSema would be the most potent single-injection GLP-1-class medication on the market.
What Analysts Expect It to Cost
Novo Nordisk has not announced CagriSema pricing. But Wall Street analysts, industry observers, and pricing strategists have offered estimates based on several factors:
| Pricing Model | Estimated Monthly Cost | Rationale |
|---|---|---|
| Premium to Wegovy | $1,500–$1,800/mo list | Superior efficacy justifies 10–30% premium over Wegovy's $1,349 list |
| Parity with Wegovy | $1,349/mo list | Novo replaces Wegovy franchise, maintains list price |
| Self-pay program pricing | $349–$499/mo | In line with NovoCare Wegovy self-pay to maintain competitiveness |
| Medicare/negotiated | $245–$300/mo | Consistent with IRA-negotiated semaglutide pricing framework |
💡 The list price is increasingly irrelevant. What matters is the self-pay program price and the negotiated Medicare/Medicaid price. Novo Nordisk will almost certainly launch CagriSema with a self-pay option in the $349–$499 range to remain competitive with LillyDirect Zepbound and its own NovoCare Wegovy program.
How CagriSema Pricing Affects the Compounded Market
CagriSema presents both a threat and an opportunity for the compounded GLP-1 market:
The Threat
If CagriSema delivers meaningfully better outcomes than semaglutide and launches with an aggressive self-pay program ($349–$499), it could pull patients from compounded semaglutide to brand-name CagriSema. Superior clinical results at 2–3x the price of compounded sema is a compelling trade for patients who can afford it.
The Opportunity
CagriSema cannot be compounded — it is a novel combination product that requires Novo Nordisk's proprietary manufacturing. This means the compounded market retains its role as the affordable access channel for patients who cannot afford CagriSema's premium. As CagriSema draws media attention and increases interest in GLP-1 medications broadly, some of that demand will flow to compounded alternatives.
The Competitive Landscape CagriSema Enters
| Product | Type | Avg Weight Loss | Monthly Cost Range |
|---|---|---|---|
| CagriSema (projected) | Brand combo | ~22–25% | $349–$499 (self-pay est.) |
| Zepbound (tirzepatide) | Brand | ~22% | $299–$449 (LillyDirect) |
| Wegovy (semaglutide) | Brand | ~17% | $349 (NovoCare) |
| Foundayo (orforglipron) | Brand oral | ~15–17% | $149–$299 (NovoCare est.) |
| Compounded semaglutide | Compounded | ~17% | $99–$199 |
| Compounded tirzepatide | Compounded | ~22% | $133–$299 |
CagriSema will compete directly with Zepbound on efficacy and pricing. For cash-pay patients, the decision will come down to whether CagriSema's incremental efficacy advantage (22–25% vs. 22%) justifies a potential price premium over LillyDirect Zepbound ($299–$449). For budget-conscious patients, compounded alternatives at $99–$199 will remain the most affordable path regardless of what CagriSema costs.
Timeline to Market
- FDA filing: Expected 2026–2027
- FDA decision: Estimated late 2027
- Commercial launch: Projected early 2028
- Self-pay program: Likely simultaneous with launch (following Wegovy/NovoCare playbook)
- Medicare coverage: Dependent on BALANCE Model implementation and CMS negotiations
What to Do Now
- Do not wait for CagriSema. The drug is 18–24 months from market. Current GLP-1 options deliver meaningful weight loss today at significantly lower cost.
- If you are already on semaglutide and losing weight, stay the course. CagriSema's incremental benefit matters most for patients who have plateaued on semaglutide alone.
- If efficacy is your top priority and budget allows, consider tirzepatide. Zepbound/compounded tirzepatide already offers ~22% average weight loss — comparable to CagriSema's trial data — and is available now.
- Watch for launch pricing announcements. Novo Nordisk will signal pricing 3–6 months before launch. We will update this article with confirmed pricing when available.
The Bottom Line
CagriSema will likely launch at a premium to Wegovy but with an aggressive self-pay program to compete with Zepbound. For most cash-pay patients, compounded semaglutide and tirzepatide at $99–$199/month will remain the best value. CagriSema's real impact will be expanding the overall GLP-1 market and providing a next-step option for patients who have maximized their response to existing medications.
⚠️ CagriSema is an investigational drug not yet approved by the FDA. All pricing in this article is speculative and based on analyst estimates. Compounded GLP-1 medications are not FDA-approved. Consult a licensed clinician for personalized treatment recommendations.